Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial. (PubMed, Lancet Oncol) - Aug 25, 2026 - P1/2 | "The combination of ifebemtinib and garsorasib showed promising anticancer activity and manageable safety profile in previously treated patients with KRASG12C-mutated metastatic colorectal cancer. Although the improvement in response rate did not reach statistical significance in the randomised study, these findings support further evaluation of ifebemtinib plus garsorasib in this population."
Clinical • Journal • P1/2 data • Colorectal Cancer • Gastrointestinal Disorder • Oncology • Renal Disease • Solid Tumor • KRAS
|
|
Baoyuan Zhang; Huaqiu Shi; Liming Zhu; Rongbo Lin; Xiangdong Cheng; Xingya Li; Ying Liu; Yinxin Zhu; Yiping Zhang; Yongzhong Luo; Yuan Yuan; Zaiqi Wang; Zhengbo Song
|